Probiostat vaginal
Natural health product licensed in Canada
- Licence holder
- Women to Women Technologies Inc.
- NPN or DIN-HM
- 80040265
- Status
- Active licence
- Licence date
- 22 February 2013
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Vaginale
- Application type
- Non traditionnelle
Oral dose analysis does not apply without an established exclusively oral route.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source |
|---|---|
| Lactobacillus delbrueckii subsp. bulgaricus Source : HA-137 | 40 Millions d'UFC |
| Lactobacillus acidophilus Source : HA-122 | 400 Millions d'UFC |
| Streptococcus salivarius subsp. thermophilus Source : HA-110 | 360 Millions d'UFC |
Non-medicinal ingredients
Stéarate de magnésium, Acide ascorbique, Maltodextrine, Bouillon trypticase soja, Gélatine
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1 Capsule | 1 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Adjunctive treatment that can help to treat vaginal yeast infections (Candidiasis).
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Source
Official Health Canada record, licence 80040265
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.